New Antibiotic Class Is Aim Of Evotec R&D Pact With Nosopharm

 
• By Sten Stovall
Bacteria
Nosopharm's new Odilorhabdin class has a novel MoA inhibiting bacterial translation • Source: Shutterstock

More from Deals

More from Business